Clinical trial · Observational
Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)
NCT03043508CI-TRIAL-00038777unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
OBJECTIVES: The primary objective of this study is to evaluate the effect of estrogen on the development of the PNET in MEN1 patients. The secondary objective is to evaluate the overall survival and disease specific survival in patients who have confirmed MEN1 with or without PNET and a pancreatic neuroendocrine tumor in relation to their hormone status. The secondary objective is to evaluate clinicopathologic features in relation to hormone status.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genetic Mutation | — | UNRESOLVED | — |
| MEN1 | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chart Review | Other | — | UNRESOLVED |
| Questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Participants With Confirmed MEN1 With PNET
- description
- Retrospective review of a prospectively maintained MEN1 database. Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
- interventionNames
- Other: Chart Review
- Behavioral: Questionnaire
- label
- Participants With Confirmed MEN1 Without PNET
- description
- Retrospective review of a prospectively maintained MEN1 database. Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
- interventionNames
- Other: Chart Review
- Behavioral: Questionnaire
Primary outcomes (1)
- measure
- Time to Pancreatic Neuroendocrine Tumors (PNET)
- timeFrame
- 10 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient cohort for this study consists of all patients within the prospectively maintained MEN1 database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center. 2. Patients with a diagnosis of MEN1 with or without PNET based on mutational analysis or defined clinical criteria were considered. 3. All patients for whom hormone status variables and survival data are available will be included. Exclusion Criteria: 1\. Due to the nature of the questions included in the prospective estrogen questionnaire, only female patients will be verbally consented to receive the questionnaire and obtain prospective data.
References
Publications (0)
Data not yet available
No reference posted for this study.